BiomX
PHGEBiomX Ltd. (NYSE American: PHGE) is a clinical-stage biotechnology company based in Israel. The company's primary business focus is the development of novel, engineered bacteriophage (phage) therapies. These therapies are designed to precisely target and eliminate specific harmful bacteria that contribute to chronic diseases, while aiming to preserve the beneficial microbiome. The company's pipeline targets therapeutic areas with significant unmet medical need, where pathogenic bacteria are a known driver of disease. BiomX is advancing programs in inflammatory bowel disease, specifically for patients with Crohn's disease who are colonized by adherent-invasive *E. coli*, and in dermatology for the treatment of acne vulgaris. Additionally, the company is developing a phage-based candidate for the potential treatment of colorectal cancer associated with *Fusobacterium nucleatum*. BiomX utilizes a proprietary platform to discover and rationally engineer natural phage combinations into targeted therapeutic candidates. The company's approach involves the identification of key bacterial pathogens, the isolation of phages that infect them, and the optimization of these phages into defined cocktail formulations. BiomX is conducting clinical trials to evaluate the safety and efficacy of its lead candidates.
PHGE · Stock Price
Historical price data
About
BiomX Ltd. (NYSE American: PHGE) is a clinical-stage biotechnology company based in Israel. The company's primary business focus is the development of novel, engineered bacteriophage (phage) therapies. These therapies are designed to precisely target and eliminate specific harmful bacteria that contribute to chronic diseases, while aiming to preserve the beneficial microbiome. The company's pipeline targets therapeutic areas with significant unmet medical need, where pathogenic bacteria are a known driver of disease. BiomX is advancing programs in inflammatory bowel disease, specifically for patients with Crohn's disease who are colonized by adherent-invasive *E. coli*, and in dermatology for the treatment of acne vulgaris. Additionally, the company is developing a phage-based candidate for the potential treatment of colorectal cancer associated with *Fusobacterium nucleatum*. BiomX utilizes a proprietary platform to discover and rationally engineer natural phage combinations into targeted therapeutic candidates. The company's approach involves the identification of key bacterial pathogens, the isolation of phages that infect them, and the optimization of these phages into defined cocktail formulations. BiomX is conducting clinical trials to evaluate the safety and efficacy of its lead candidates.